Sun Pharma’s arm inks pact with Hikma Pharmaceuticals for ILUMYA

15 Jun 2020 Evaluate
Sun Pharmaceutical Industries’ one of wholly-owned subsidiaries and Hikma Pharmaceuticals PLC (Hikma) have entered into an exclusive licensing and distribution agreement for ILUMYA, an innovative biologic product, for the Middle East & North Africa (MENA) region. ILUMYA (tildrakizumab) is an USFDA approved innovative IL-23p19 monoclonal antibody used for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. 
 
Under the terms of the licensing agreement, Hikma will be responsible for the registration and commercialization of the product in all MENA markets and Sun Pharma will be responsible for product supply. The company is eligible for upfront and milestone payments from Hikma. The term of this agreement is 15 years from first sale, with two years’ automatic renewal periods.
 
Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.

Sun Pharma Inds. Share Price

1781.00 -16.25 (-0.90%)
16-Dec-2025 10:04 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1781.00
Dr. Reddys Lab 1274.60
Cipla 1502.10
Zydus Lifesciences 923.90
Lupin 2089.75
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×